In brief
Iga Swiatek, the reigning French Open champion, has accepted a one-month suspension after testing positive for the banned substance trimetazidine.
Iga Swiatek, the 23-year-old world number two and five-time Grand Slam champion, has agreed to a one-month suspension after a doping violation linked to heart medication. The International Tennis Integrity Agency (ITIA) confirmed that Swiatek, who held the top ranking earlier this year, tested positive for trimetazidine (TMZ) in an August 2024 out-of-competition test. This sanction follows an investigation that determined the source of the positive test was a contaminated regulated medication. Given the unique circumstances of the case, including Swiatek's lack of significant fault or negligence, the ITIA issued this suspension, which she accepted on Wednesday. The Polish star faced provisional suspension starting September 12, prior to which she appealed the decision. With her successful appeal, she has now missed three tournaments—notably forfeiting her prize money from the Cincinnati Open, where she reached the semi-finals. According to Karen Moorhouse, ITIA’s chief executive, the investigation found the presence of TMZ stemmed from a disturbed medication, which is recognized as regulated in Poland but lacks similar designation in other countries. Nevertheless, this situation underscores the complexity of the global regulation of medications. Swiatek's appeal detailed the confirmation of a contaminated product and noted she would be eligible to compete again on December 4, 2024, following the lapsing of her ineligibility period. The player aimed to return stronger from this challenging experience, as the tennis community prepares to follow her recovery journey closely. More updates are expected as the tennis world anticipates her return.
